Chemical and thyroid hormone profile of the bone marrow interstitial fluid in hematologic disorders and patients without primary hematologic disorders
Abstract
Bone marrow interstitial fluid (BMIF) has not been well characterized. BMIF was isolated from 60 patients including plasma cell dyscrasias (PCD, n = 33), other primary hematologic disorders (OHD, n = 15), and patients with secondary or nonhemtologic disorders (NHD, n = 12) and analyzed for an array of chemical constituents. These included total cholesterol, glucose, phosphate, creatinine, urea, total protein, albumin, globulins, total bilirubin, aspartate aminotransferase, lactate dehydrogenase, sodium, osmolarity, free triiodothyronine (free T3), total triiodothyronine (total T3), and free tetraiodothyronin...
Source: Hematological Oncology - December 1, 2017 Category: Hematology Authors: Eilon Krashin, Martin Ellis, Keren Cohen, Maya Viner, Eran Neumark, Gloria Rashid, Osnat Ashur ‐Fabian Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
In this study, we analysed 86 consecutive MM patients with a first relapse after prior ASCT receiving either a second ASCT or conventional chemotherapy. After a median follow‐up of 37.7 months since first relapse, 54 (62.8%) patients were still alive and 29 (33.7%) without progression. Sixty‐one (71.0%) patients received ASCT2 and had better progression‐free survival (PFS) (30.2 versus 13.0 mo; P = .0262) and overall survival (OS) rates (129.6 versus 33.5 mo; P = .0003) compared with 25 (29.0%) patients with conventional treatment. Patients relapsing later than 12 months after ASCT1 benefitted from a second A...
Source: Hematological Oncology - December 1, 2017 Category: Hematology Authors: Ursina G össi, Barbara Jeker, Behrouz Mansouri Taleghani, Ulrike Bacher, Urban Novak, Daniel Betticher, Thomas Egger, Thilo Zander, Thomas Pabst Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Clinical pharmacokinetics of oral drugs in the treatment of multiple myeloma
Hematological Oncology, EarlyView. (Source: Hematological Oncology)
Source: Hematological Oncology - November 27, 2017 Category: Hematology Source Type: research
---
Hematological Oncology, Ahead of Print. (Source: Hematological Oncology)
Source: Hematological Oncology - November 27, 2017 Category: Hematology Source Type: research
Role of BMI and age in predicting pathologic vertebral fractures in newly diagnosed multiple myeloma patients: A retrospective cohort study
Hematological Oncology, EarlyView. (Source: Hematological Oncology)
Source: Hematological Oncology - November 6, 2017 Category: Hematology Source Type: research
---
Hematological Oncology, Ahead of Print. (Source: Hematological Oncology)
Source: Hematological Oncology - November 6, 2017 Category: Hematology Source Type: research
Relapse in stage I(E) diffuse large B ‐cell lymphoma
Hematological Oncology, EarlyView. (Source: Hematological Oncology)
Source: Hematological Oncology - October 30, 2017 Category: Hematology Source Type: research
Alternating R ‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma
Hematological Oncology,Volume 36, Issue 1, Page 110-115, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 30, 2017 Category: Hematology Source Type: research
---
Hematological Oncology, Ahead of Print. (Source: Hematological Oncology)
Source: Hematological Oncology - October 30, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 110-115, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 30, 2017 Category: Hematology Source Type: research
Relapse in stage I(E) diffuse large B ‐cell lymphoma
Abstract
Despite a general favourable outcome in limited stage diffuse large B‐cell lymphoma (DLBCL), relapses occur in about 10 to 20% of patients. Prognostic models only partially identify patients at risk for relapse. Moreover, it is not known whether the outcome after such a relapse is similar to the outcome after relapse in advanced stages. From January 2004 through December 2012, all newly diagnosed patients with stage I(E) DLBCL were retrospectively analysed from 2 clinical databases to investigate the relapse pattern and outcome in relation to initial treatment and clinical characteristics. In 126 patients (media...
Source: Hematological Oncology - October 30, 2017 Category: Hematology Authors: Marcel Nijland, Karin Boslooper, Gustaaf Imhoff, Robbie Kibbelaar, Peter Joosten, Huib Storm, Eric N. Roon, Arjan Diepstra, Hanneke C. Kluin ‐Nelemans, Mels Hoogendoorn Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Prompt detection of L ‐asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas
Hematological Oncology, EarlyView. (Source: Hematological Oncology)
Source: Hematological Oncology - October 20, 2017 Category: Hematology Source Type: research
Frequent expression of CD30 in extranodal NK/T ‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy
Hematological Oncology,Volume 36, Issue 1, Page 166-173, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 20, 2017 Category: Hematology Source Type: research
---
Hematological Oncology, Ahead of Print. (Source: Hematological Oncology)
Source: Hematological Oncology - October 20, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 166-173, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - October 20, 2017 Category: Hematology Source Type: research
